Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...
A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...
The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...
The United States Cutaneous Lymphoma Consortium is a multidisciplinary society of physicians which use collaborative research and education to improve the quality of life and prognosis of patients ...
Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...
Peripheral T-cell lymphomas are a rare and heterogeneous type of lymphoma, with geographical and ethnic variations in histological subtypes that differ across the world.1 In The Lancet Haematology, ...
Mr. T shared his own daily prayer habits with Beliefnet.
Our study underscores the unique epidemiological profile of peripheral T-cell lymphoma in Latin America, with a high ...
Bioheng Therapeutics US LLC has obtained IND approval from the FDA for CTD-402, a CD7-targeted universal CAR T-cell therapy, ...
A new study reveals concerning risks associated with tattoos, including higher rates of lymphoma and skin cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback